chr17-7676387-C-T
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_000546.6(TP53):c.91G>A(p.Val31Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000156 in 1,613,564 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000546.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TP53 | NM_000546.6 | c.91G>A | p.Val31Ile | missense_variant | 3/11 | ENST00000269305.9 | NP_000537.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TP53 | ENST00000269305.9 | c.91G>A | p.Val31Ile | missense_variant | 3/11 | 1 | NM_000546.6 | ENSP00000269305.4 |
Frequencies
GnomAD3 genomes AF: 0.0000988 AC: 15AN: 151806Hom.: 1 Cov.: 30
GnomAD3 exomes AF: 0.000252 AC: 63AN: 249510Hom.: 1 AF XY: 0.000229 AC XY: 31AN XY: 135562
GnomAD4 exome AF: 0.000163 AC: 238AN: 1461642Hom.: 3 Cov.: 47 AF XY: 0.000161 AC XY: 117AN XY: 727108
GnomAD4 genome AF: 0.0000922 AC: 14AN: 151922Hom.: 1 Cov.: 30 AF XY: 0.0000808 AC XY: 6AN XY: 74260
ClinVar
Submissions by phenotype
Li-Fraumeni syndrome 1 Pathogenic:1Uncertain:2Benign:2
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Dec 10, 2015 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Mendelics | May 15, 2020 | - - |
Likely pathogenic, flagged submission | reference population | Soonchunhyang University Bucheon Hospital, Soonchunhyang University Medical Center | Mar 18, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Apr 11, 2023 | This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. - |
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Hereditary cancer-predisposing syndrome Benign:3
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | May 20, 2020 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 22, 2020 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | Nov 25, 2021 | - - |
not provided Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Sep 16, 2020 | - - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 27, 2017 | Variant summary: The c.91G>A (p.Val31Ile) in TP53 gene is a missense change that involves a conserved nucleotide. The variant is located just outside of the p53 transactivation domain. Although 4/5 in silico tools predict benign outcome, in the functional studies the variant displayed moderately reduced cell proliferation suppressing activity as well as transcriptional activity on p21 (CDKN1A) and MDM2 promoters, but not on the BAX promoter compared to wt-tp53 (Yamada, 2007). In addition, it is also classified as functionally competent variant in TP53 database. The variant is present in the large control population dataset of ExAC and gnomAD at a similar frequencies of 0.00026 (31/118406 and 58/275552 chromosomes tested, respectively), predominantly in individuals of East Asian descent (0.00353; 30/ 8498 chromosomes and 58/18782 chromosomes tested) including one homozygote. These frequencies exceed the maximal expected frequency of a pathogenic allele (0.000047) in this gene. The variant has been reported in several cancer-affected individuals without evidence for causality (Toguchida, 1992; Lee, 2010; Yamada, 2007; Yamaguchi, 2016) and is generally regarded as a polymorphism. In addition, one individual dx with thyroid carcinoma tested positive for BRAF V600E, further supporting benign outcome of the variant of interest. The variant was also identified in one internal LCA specimen in co-occurrence with a known pathogenic variant in MSH6 c.4068_4071dupGATT (p.K1358fs*2). Lastly, multiple reputable databases/clinical laboratories cite the variant with classification of Likely Benign. Taking all lines of evidence into consideration, this variant has been classified as Benign. - |
not specified Benign:1Other:1
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Oct 13, 2017 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Hereditary breast ovarian cancer syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | research | Cancer Genomics Group, Japanese Foundation For Cancer Research | May 01, 2019 | - - |
Li-Fraumeni syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Breast and/or ovarian cancer Benign:1
Likely benign, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Feb 23, 2023 | - - |
TP53-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 12, 2019 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at